BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients

被引：31

作者：

Gilli, Stefanie ^{[1
]}

Novak, Urban ^{[1
]}

Taleghani, Behrouz Mansouri ^{[2
]}

Baerlocher, Gabriela M. ^{[2
]}

Leibundgut, Kurt ^{[3
]}

Banz, Yara ^{[4
]}

Zander, Thilo ^{[5
]}

Betticher, Daniel ^{[6
]}

Egger, Thomas ^{[7
]}

Rauch, Daniel ^{[8
]}

Pabst, Thomas ^{[1
]}

机构：

[1] Univ Hosp Bern, Dept Med Oncol, CH-3010 Bern, Switzerland

[2] Univ Hosp Bern, Dept Hematol, Bern, Switzerland

[3] Univ Hosp Bern, Dept Pediat Hematooncol, Inselspital, Bern, Switzerland

[4] Univ Bern, Inst Pathol, Bern, Switzerland

[5] Kantonsspital, Dept Oncol, Luzern, Switzerland

[6] Kantonsspital, Dept Oncol, Fribourg, Switzerland

[7] Kantonsspital, Dept Oncol, Solothurn, Switzerland

[8] Regionalspital, Dept Oncol, Thun, Switzerland

来源：

ANNALS OF HEMATOLOGY | 2017年 / 96卷 / 03期

关键词：

Autologous; Stem cell; Transplantation; Bendamustine; Lymphoma; Beam; BeEAM; BCNU; Prognosis; Survival; High dose; Chemotherapy; STEM-CELL TRANSPLANTATION; NON-HODGKINS-LYMPHOMA; HIGH-DOSE CHEMOTHERAPY; BONE-MARROW-TRANSPLANTATION; MULTICENTER PHASE-II; B-CELL; MANTLE CELL; PLUS RITUXIMAB; CONVENTIONAL CHEMOTHERAPY; INTENSIFIED CHEMOTHERAPY;

D O I：

10.1007/s00277-016-2900-y

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BEAM with BCNU is commonly used for conditioning treatment followed by autologous stem cell transplantation (ASCT). However, pulmonary toxicity and availability issues associated with BCNU prompted us to evaluate bendamustine-replacing BCNU (BeEAM). We analyzed 39 lymphoma patients receiving BeEAM conditioning with 200 mg/m(2) bendamustine at days -7 and -6. The median duration until neutrophil recovery was 11 days, and 15 days for platelet recovery (> 20 g/L). The most common grade 3/4 non-hematologic toxicities comprised mucosal side effects (27 pts.). Pulmonary toxicity was observed in one patient (2.5%), and one patient died of septic complications. The CR rate increased from 33% to 74% 100 days after ASCT. After a median follow-up of 18.5 months, progression and death each occurred in 11 patients (28%). Median progression-free and overall survival at 2 years were 69% and 72%. Our data suggest that BeEAM conditioning using bendamustine is safe and results in promising survival rates.

引用

页码：421 / 429

页数：9

共 37 条

[1] Risk Factors and Outcome of Pulmonary Complications After Autologous Hematopoietic Stem Cell Transplant [J].

Afessa, Bekele ;

Abdulai, Raolat M. ;

Kremers, Walter K. ;

Hogan, William J. ;

Litzow, Mark R. ;

Peters, Steve G. .

CHEST, 2012, 141 (02) :442-450

[2]

Ager S, 1996, BONE MARROW TRANSPL, V17, P335

[3] Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens [J].

Ardeshna, KM ;

Kakouros, N ;

Qian, W ;

Powell, MG ;

Saini, N ;

D'Sa, S ;

Mackinnon, S ;

Hoskin, PJ ;

Goldstone, AH ;

Linch, DC .

BRITISH JOURNAL OF HAEMATOLOGY, 2005, 130 (03) :363-372

[4] Improved outcome with busulfan, melphalan and thiotepa conditioning in autologous hematopoietic stem cell transplant for relapsed/refractory Hodgkin lymphoma [J].

Bains, Tarunpreet ;

Chen, Andy I. ;

Lemieux, Andrew ;

Hayes-Lattin, Brandon M. ;

Leis, Jose F. ;

Dibb, William ;

Maziarz, Richard T. .

LEUKEMIA & LYMPHOMA, 2014, 55 (03) :583-587

[5] CD34+selected versus unselected autologous stem cell transplantation in patients with advanced-stage mantle cell and diffuse large B-cell lymphoma [J].

Berger, Martin D. ;

Branger, Giacomo ;

Leibundgut, Kurt ;

Baerlocher, Gabriela M. ;

Seipel, Katja ;

Mueller, Beatrice U. ;

Gregor, Michael ;

Ruefer, Axel ;

Pabst, Thomas .

LEUKEMIA RESEARCH, 2015, 39 (06) :561-567

[6] High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy inpatients with inflammatory breast cancer [J].

Cagnoni, PJ ;

Nieto, Y ;

Shpall, EJ ;

Bearman, SI ;

Barón, AE ;

Ross, M ;

Matthes, S ;

Dunbar, SE ;

Jones, RB .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (05) :1661-1668

[7] Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation [J].

Chen, Yi-Bin ;

Lane, Andrew A. ;

Logan, Brent R. ;

Zhu, Xiaochun ;

Akpek, Goerguen ;

Aljurf, Mahmoud. D. ;

Artz, Andrew S. ;

Bredeson, Christopher N. ;

Cooke, Kenneth R. ;

Ho, Vincent T. ;

Lazarus, Hillard M. ;

Olsson, Richard F. ;

Saber, Wael ;

McCarthy, Philip L. ;

Pasquini, Marcelo C. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (06) :1046-1053

[8] Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group [J].

Fischer, Kirsten ;

Cramer, Paula ;

Busch, Raymonde ;

Stilgenbauer, Stephan ;

Bahlo, Jasmin ;

Schweighofer, Carmen D. ;

Boettcher, Sebastian ;

Staib, Peter ;

Kiehl, Michael ;

Eckart, Michael J. ;

Kranz, Gabriele ;

Goede, Valentin ;

Elter, Thomas ;

Buehler, Andreas ;

Winkler, Dirk ;

Kneba, Michael ;

Doehner, Hartmut ;

Eichhorst, Barbara F. ;

Hallek, Michael ;

Wendtner, Clemens-Martin .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (26) :3559-3566

[9] COMPARISON OF A STANDARD REGIMEN (CHOP) WITH 3 INTENSIVE CHEMOTHERAPY REGIMENS FOR ADVANCED NON-HODGKINS-LYMPHOMA [J].

FISHER, RI ;

GAYNOR, ER ;

DAHLBERG, S ;

OKEN, MM ;

GROGAN, TM ;

MIZE, EM ;

GLICK, JH ;

COLTMAN, CA ;

MILLER, TP .

NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (14) :1002-1006

[10] Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA [J].

Fitoussi, Olivier ;

Belhadj, Karim ;

Mounier, Nicolas ;

Parrens, Marie ;

Tilly, Herve ;

Salles, Gilles ;

Feugier, Pierre ;

Ferme, Christophe ;

Ysebaert, Loic ;

Gabarre, Jean ;

Herbrecht, Raoul ;

Janvier, Maud ;

Van den Neste, Eric ;

Morschhauser, Franck ;

Casasnovas, Olivier ;

Ghesquieres, Herve ;

Anglaret, Bruno ;

Brechignac, Sabine ;

Haioun, Corinne ;

Gisselbrecht, Christian .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (08) :1136-1143

← 1 2 3 4 →